Dear Pharmaceutical Management Agency,

Pursuant to the Official Information Act 1982, I request the following information:

All internal briefing papers, policy documents, legal opinions, or board papers prepared by Pharmac regarding the implications of the New Zealand-India Free Trade Agreement's pharmaceutical and medical devices provisions - specifically the GMP mutual recognition and regulatory acceptance provisions - for Pharmac's competitive procurement processes for vaccines, during the period 1 January 2024 to date.

All internal documents, briefing papers, or board papers that address the question of whether Indian pharmaceutical manufacturers - including specifically the Serum Institute of India - would be eligible to participate in future Pharmac vaccine procurement processes under the terms of the NZ-India FTA, and on what regulatory basis.

A summary of the legal and procedural framework under which Pharmac's normal competitive procurement processes can be suspended or bypassed in the event of a declared public health emergency, including:

a. The statutory basis for any such suspension.

b. The authority (Minister, Director-General, or other) required to activate emergency procurement.

c. Whether Pharmac has developed or updated any emergency procurement protocols since the conclusion of the COVID-19 pandemic response.

The complete terms of the current Principal Supply agreement with Pfizer for the Comirnaty COVID-19 vaccine (awarded August 31, 2025), including:

a. Contract value.

b. Volume commitments.

c. Indemnity provisions (if any).

d. Intellectual property terms.

e. Termination clauses.

Note: I acknowledge that Pharmac has previously withheld contract terms on commercial sensitivity grounds. I request that Pharmac reassess this position in light of the public interest in transparency regarding publicly-funded vaccine procurement, and that any decision to withhold be accompanied by a full explanation of how commercial sensitivity outweighs the public interest under section 9(1) of the Official Information Act 1982.

All correspondence between Pharmac and Helen Clark - in any capacity - regarding vaccine procurement, the NZ-India FTA, or pandemic preparedness, during the period 1 January 2024 to date.

If any information is withheld, I request that the grounds for withholding be specified with reference to the relevant section of the Official Information Act 1982.

I trust this request can be completed within 20 working days as required by the Act.

Yours faithfully,

Penny Claridge